Goldman Sachs

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded PerkinElmer and Affymetrix but downgraded Thermo Fisher Scientific.

The downgrades to Illumina and Waters reflect larger worries the investment bank has about the end markets of life science tools firms.

In a research note, the investment house cited concerns about Cepheid's high price-to-sale ratio but said that the firm's installed base is expected to grow 27 percent year over year in 2011.

A report on Goldman Sachs' evaluations of Illumina and Life Technologies' desktop next-generation sequencing platforms once again was the most-read story on GWDN during the past week.

The investment firm lowered EPS estimates for Illumina on an expected shift to the MiSeq platform from the HiSeq system, but said that in a short amount of time Illumina's desktop sequencer would overtake Ion Torrent's PGM as the market leader.

Though Illumina has been predicting a second round of association studies run on chips containing rare variant content, CEO Jay Flatley said that the market is "at the very beginning" of this new phase, which Illumina refers to as "rich GWAS."

An analyst at the investment firm said that the expanded production of Illumina's HiSeq sequencing platform is expected to result in sequential revenue growth in the first and second quarters of 2011, but revenue growth will likely abate in the third quarter.

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.